Whenever the Bean photo pops up then you know it marks the start of the annual meeting of the American Society of Clinical Oncology (ASCO).
Ahead of this year’s abstract data palooza, I thought it would be a nice idea to highlight some of the key sessions of interest and important abstracts within.
There are quite a few new molecules to watch out for in early drug development, plus some important phase 3 trial readouts to consider, especially on the combination front.
It will be hard act to beat or even follow the phase 3 lung cancer clinical trials plenary at AACR18 last month, but here goes…
We have selected 11 key areas that may be useful to watch out for as a starting point ahead of the abstract data dump expected tomorrow at 5pm.